Zolmitriptan (CED0006350)

Record Information

Version

1.0

Creation Date

2009-07-21 20:26:34 UTC

Update Date

2026-05-14 16:25:22 UTC

SynCED ID

CED0006350

Secondary Accession Numbers

CHEM002167
T3D2748

Identification

Common Name

Zolmitriptan

Class

Small Molecule

Description

Zolmitriptan is an exogenous organic compound with the formula C16H21N3O2 and an average molecular weight of 287.36 g/mol. It exists as a solid at room temperature. Zolmitriptan belongs to the tryptamines and derivatives, a subclass of indoles and derivatives within the organic compounds. This compound is used as a serotonergic agonist, a vasoconstrictor agent, and an anti-inflammatory drug. It is found in healthcare, pharmaceuticals, and veterinary products as an analgesic, as well as in electrical and electronic equipment including electric hearing aids and electrically stimulated smoking devices, and household cleaning and consumer products such as tobacco pipes, cigar cigarettes, non electric simulated smoking devices, and other smoking requisites. Recorded exposure routes include nasal and oral administration. The compound interacts with several protein targets, acting as an agonist of 5-hydroxytryptamine receptor 1A (HTR1A), 5-hydroxytryptamine receptor 2A (HTR2A), 5-hydroxytryptamine receptor 2B (HTR2B), and 5-hydroxytryptamine receptor 7 (HTR7). It also targets 5-hydroxytryptamine receptor 4 (HTR4), 5-hydroxytryptamine receptor 1F (HTR1F), 5-hydroxytryptamine receptor 1B (HTR1B), 5-hydroxytryptamine receptor 1D (HTR1D), and one other protein. Zolmitriptan binds with high affinity to human 5-HT1B and 5-HT1D receptors leading to cranial blood vessel constriction. Current theories proposed to explain the etiology of migraine headache suggest that symptoms are due to local cranial vasodilatation and/or to the release of sensory neuropeptides (vasoactive intestinal peptide, substance P and calcitonin gene-related peptide) through nerve endings in the trigeminal system. The therapeutic activity of zolmitriptan for the treatment of migraine is most likely attributed to the agonist effects at the 5HT1B/1D receptors on intracranial blood vessels and sensory nerves of the trigeminal system.

Contaminant Type

Amine
Anti-Inflammatory Agent
Anti-Migraine Agent
Drug
Ester
Ether
Metabolite
Organic Compound
Selective Serotonin Agonist
Serotonin 5-HT1 Receptor Agonist
Serotonin Agonist
Serotonin Antagonist
Serotonin Receptor Agonist
Synthetic Compound
Vasoconstrictor Agent

Chemical Structure

MOL SDF PDB SMILES InChI

Synonyms

Value	Source
311c90	ChEBI
4-[[3-(2-Dimethylaminoethyl)-1H-indol-5-yl]methyl]oxazolidin-2-one	ChEBI
Zipton	ChEBI
Zolmitriptanum	ChEBI
Zomig	ChEBI
Zomigoro	ChEBI
Zominat	ChEBI
ZMT	HMDB
Ferrer brand OF zolmitriptan	HMDB
AscoTop	HMDB
Zeneca brand OF zolmitriptan	HMDB
4-((3-(2-(Dimethylamino)ethyl)-1H-indol-5-yl)methyl)-2-oxazolidinone	HMDB
AstraZeneca brand OF zolmitriptan	HMDB
Flezol	HMDB
Astra brand OF zolmitriptan	HMDB

Chemical Formula

C₁₆H₂₁N₃O₂

Average Molecular Mass

287.357 g/mol

Monoisotopic Mass

287.163 g/mol

CAS Registry Number

139264-17-8

IUPAC Name

(4S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one

Traditional Name

zomig

SMILES

CN(C)CCC1=CNC2=CC=C(C[C@H]3COC(=O)N3)C=C12

InChI Identifier

InChI=1S/C16H21N3O2/c1-19(2)6-5-12-9-17-15-4-3-11(8-14(12)15)7-13-10-21-16(20)18-13/h3-4,8-9,13,17H,5-7,10H2,1-2H3,(H,18,20)/t13-/m0/s1

InChI Key

ULSDMUVEXKOYBU-ZDUSSCGKSA-N

Chemical Taxonomy

Description

Belongs to the class of organic compounds known as tryptamines and derivatives. Tryptamines and derivatives are compounds containing the tryptamine backbone, which is structurally characterized by an indole ring substituted at the 3-position by an ethanamine.

Kingdom

Organic compounds

Super Class

Organoheterocyclic compounds

Class

Indoles and derivatives

Sub Class

Tryptamines and derivatives

Direct Parent

Tryptamines and derivatives

Alternative Parents

Substituents

Tryptamine
3-alkylindole
Indole
Aralkylamine
Oxazolidinone
Substituted pyrrole
Benzenoid
Oxazolidine
Pyrrole
Heteroaromatic compound
Carbamic acid ester
Carbonic acid derivative
Tertiary amine
Tertiary aliphatic amine
Oxacycle
Azacycle
Hydrocarbon derivative
Organic oxide
Organopnictogen compound
Organooxygen compound
Organonitrogen compound
Organic oxygen compound
Organic nitrogen compound
Carbonyl group
Amine
Aromatic heteropolycyclic compound

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

tryptamines (CHEBI:10124 )

Biological Properties

Status

Detected and Not Quantified

Origin

Exogenous

Cellular Locations

Cytoplasm
Extracellular
Membrane

Biofluid Locations

Not Available

Tissue Locations

Not Available

Applications

Biological Roles

serotonergic agonist ?

Chemical Roles

Not Available

Organoleptic Effects

Not Available

Physical Properties

State

Solid

Appearance

White powder.

Experimental Properties

Property	Value
Melting Point	Not Available
Boiling Point	Not Available
Solubility	1.90e-01 g/L

Predicted Properties

Property	Value	Source
Water Solubility	0.19 g/L	ALOGPS
logP	2.25	ALOGPS
logP	2.04	ChemAxon
logS	-3.2	ALOGPS
pKa (Strongest Acidic)	13	ChemAxon
pKa (Strongest Basic)	9.55	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	2	ChemAxon
Hydrogen Donor Count	2	ChemAxon
Polar Surface Area	57.36 Å²	ChemAxon
Rotatable Bond Count	5	ChemAxon
Refractivity	82.44 m³·mol⁻¹	ChemAxon
Polarizability	31.65 Å³	ChemAxon
Number of Rings	3	ChemAxon
Bioavailability	Yes	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Spectra

Spectrum Type	Description	Splash Key	Deposition Date	View
Predicted GC-MS	Predicted GC-MS Spectrum	splash10-0a4i-9140000000-8d3d0029a006c9f3ba49	Not Available	View Spectrum
Predicted GC-MS	Predicted GC-MS Spectrum	Not Available	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-000i-1390000000-5eb2470575d7a40b35dd	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-000i-0390000000-d91f1c70da42e9043a7b	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-0a5l-4970000000-d6feef1af8c3d273bbe4	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-000i-0090000000-c74574aba82b34fbcfc1	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-000i-0090000000-2eab59f442a95263f917	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-000l-1290000000-4b3bf33424e3bd5259dc	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-00du-2910000000-46170261887fb6bb2a86	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-000i-2090000000-33a4ce8acdaace7f51cb	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-0006-9060000000-dc863874d2aa1113bab8	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-0006-9100000000-ee342e011f9a483f3bed	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-000i-2090000000-59447660b4ff1ee0d5a8	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-0a4i-9170000000-ae1576ef07f3ffa1d131	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-0a4i-9320000000-d3b22cc0b99199c251b7	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-000i-0090000000-85a896e022373a149d53	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-000l-0090000000-78d6b93aa92bfd05a777	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-0006-5970000000-3b90408e256cd6d8ae19	Not Available	View Spectrum

Toxicity Profile

Toxicity Values

Toxicity Value	Organism	Dose Descriptor	Route of Exposure	Predicted or Experimental	Toxicity Rating	Reference
510.0 Log mg/kg [290:910]	Rat	LD50	oral	predicted	Not Available	Not Available

Toxicity / Toxin Class

Not Available

Mechanism of Toxicity

Zolmitriptan binds with high affinity to human 5-HT_1B and 5-HT_1D receptors leading to cranial blood vessel constriction. Current theories proposed to explain the etiology of migraine headache suggest that symptoms are due to local cranial vasodilatation and/or to the release of sensory neuropeptides (vasoactive intestinal peptide, substance P and calcitonin gene-related peptide) through nerve endings in the trigeminal system. The therapeutic activity of zolmitriptan for the treatment of migraine headache can most likely be attributed to the agonist effects at the 5HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.

Carcinogenicity (IARC Classification)

No indication of carcinogenicity to humans (not listed by IARC).

Minimum Risk Level

Not Available

Symptoms

Not Available

Treatment

There is no specific antidote to zolmitriptan. In cases of severe intoxication, intensive care procedures are recommended, including establishing and maintaining a patent airway, ensuring adequate oxygenation and ventilation, and monitoring and support of the cardiovascular system. (4)

Health Effects

Health Effect	Relationship	Direction	Description	Reference
migraine	Not Available	Not Available	A brain disease that is characterized by moderate to severe headaches, nausea, extreme sensitivity to light and sound and intense unilaterial throbbing or pulsing. (DO)	PMC12709874 , PMC8459588

Exposure Sources

Source ID	Source	Sector	Reference
CEDs000370	Analgesics?Analgesics are a class of synthetic chemicals designed to alleviate pain.	Healthcare, pharmaceuticals & veterinary products	Not Available
CEDs000516	Electric Hearing Aids?Electric hearing aids are small electronic devices designed to amplify sound for individuals with hearing loss.	Electrical & Electronic Equipment	PubChem
CEDs000518	Electrically Stimulated Smoking Devices?Electrically stimulated smoking devices, commonly known as e-cigarettes or vape pens, utilize electrical components to heat a liquid solution, often containing nicotine, flavorings, and other additives, to produce an aerosol for inhalation.	Electrical & Electronic Equipment	PubChem
CEDs000545	Food Preservation?Food preservation often involves the use of synthetic chemicals, such as preservatives, flavor enhancers, and color additives, to extend shelf life and enhance the sensory qualities of food products.	Food, food processing & cookware	PubChem
CEDs000556	Cigar Cigarettes?Cigar cigarettes are a source of synthetic chemical contamination due to the combustion of various tobacco blends and additives.	Household cleaning & consumer products	PubChem
CEDs000559	Non Electric Simulated Smoking Devices?Non-electric simulated smoking devices, often designed to mimic the experience of smoking without combustion, can be sources of synthetic chemical contamination due to the materials and chemicals used in their construction and operation.	Household cleaning & consumer products	PubChem
CEDs000560	Other Smoking Requisites?Other smoking requisites, including items such as lighters, matches, and rolling papers, can introduce synthetic chemical contamination through various components and additives.	Household cleaning & consumer products	PubChem
CEDs000566	Tobacco Pipes?Tobacco pipes, often made from materials such as plastic, wood, or metal, can serve as sources of synthetic chemical contamination due to the residues left by tobacco products.	Household cleaning & consumer products	PubChem
CEDs000569	Tobacco Smoke Filters?Tobacco smoke filters are designed to reduce the inhalation of harmful substances in cigarette smoke, including tar and other particulate matter.	Household cleaning & consumer products	PubChem
CEDs000580	Manufacture Preparation Of Tobacco Products?The manufacture and preparation of tobacco products involve various processes that can result in the introduction of synthetic chemicals into the environment.	Industrial manufacturing & chemical processing	PubChem
CEDs000611	Anti Perspirants Or Body Deoderants?Antiperspirants and body deodorants commonly contain synthetic chemicals such as aluminum compounds, parabens, and synthetic fragrances.	Personal care & cosmetics	PubChem
CEDs000617	Lip Care Products?Lip care products, including lipsticks, balms, and glosses, often contain a variety of synthetic chemicals such as parabens, phthalates, and synthetic fragrances.	Personal care & cosmetics	PubChem
CEDs000632	Apparel?Apparel production often involves the use of various synthetic chemicals, including dyes, finishing agents, and preservatives.	Textiles, leather & furnishings	PubChem
CEDs000650	Purses Luggage Hand Bags?Purses, luggage, and handbags are often manufactured using synthetic materials such as polyvinyl chloride (PVC), polyurethane, and various types of nylon.	Textiles, leather & furnishings	PubChem
CEDs000651	Purses Money Bags Wallets?Purses, money bags, and wallets are often manufactured using synthetic materials, including plastics, polyurethanes, and various treated fabrics.	Textiles, leather & furnishings	PubChem
CEDs000671	Airplanes And Helicopters?Airplanes and helicopters are significant sources of synthetic chemical contamination primarily through the use of aviation fuels, lubricants, and de-icing agents.	Aviation & Aerospace	PubChem
CEDs000685	Ceramics?Ceramics can be a source of synthetic chemical contamination through various additives and processing agents used in their production.	Building & Construction	PubChem
CEDs000696	Nanotechnology?Nanotechnology involves the manipulation of materials at the molecular or atomic level, typically within the range of 1 to 100 nanometers.	Industrial manufacturing & chemical processing	PubChem
CEDs000735	Explosives?Explosives are chemical compounds or mixtures designed to undergo rapid decomposition, releasing energy in the form of gas and heat.	Defense & military infrastructure	PubChem
CEDs000741	Pigment Pastes?Pigment pastes are concentrated dispersions of pigments used to impart color and properties to materials.	Paper, pulp & fiber products	PubChem
CEDs000744	Water, Wastewater, & Sewage Treatment?Water, wastewater, and sewage treatment processes are critical for managing and mitigating pollutants in water systems.	Wastewater, sanitation & biosolids	PubChem

Pathways

2 pathwaysPathway Source: PathBank

Zolmitriptan Mechanism of Action Action Pathway

Zolmitriptan Drug Metabolism Action Pathway

Targets

Structure	Protein	UniProt ID	Organism	Relationship	Details
Click to view 3D structure	5-hydroxytryptamine receptor 1A	P08908	Humans	Predicted (SEA)	Prediction Confidence Score 0.639 Applicability Domain 1.0 Statistical Significance 0.0011 Supporting Reference Compounds 953 E-value 8.32987
Click to view 3D structure	5-hydroxytryptamine receptor 1D	P28221	Humans	Predicted (SEA)	Prediction Confidence Score 0.636 Applicability Domain 1.0 Statistical Significance 3.10e-04 Supporting Reference Compounds 365 E-value 2.41333
Click to view 3D structure	5-hydroxytryptamine receptor 1B	P28222	Humans	Predicted (SEA)	Prediction Confidence Score 0.636 Applicability Domain 1.0 Statistical Significance 2.50e-04 Supporting Reference Compounds 337 E-value 1.94623
Click to view 3D structure	5-hydroxytryptamine receptor 2A	P28223	Humans	Predicted (SEA)	Prediction Confidence Score 0.534 Applicability Domain 0.627 Statistical Significance 0.0032 Supporting Reference Compounds 955 E-value 24.6004
Click to view 3D structure	5-hydroxytryptamine receptor 2C	P28335	Humans	Predicted (SEA)	Prediction Confidence Score 0.52 Applicability Domain 0.627 Statistical Significance 0.0025 Supporting Reference Compounds 823 E-value 19.8516
Click to view 3D structure	D(2) dopamine receptor	P61169	Rat	Predicted (SEA)	Prediction Confidence Score 0.497 Applicability Domain 1.0 Statistical Significance 0.0053 Supporting Reference Compounds 528 E-value 41.2601
Click to view 3D structure	5-hydroxytryptamine receptor 2A	P14842	Rattus norvegicus	Predicted (SEA)	Prediction Confidence Score 0.489 Applicability Domain 0.544 Statistical Significance 0.0026 Supporting Reference Compounds 380 E-value 20.1629
Click to view 3D structure	5-hydroxytryptamine receptor 1D	P79400	Sus scrofa	Predicted (SEA)	Prediction Confidence Score 0.486 Applicability Domain 0.544 Statistical Significance 8.00e-05 Supporting Reference Compounds 18 E-value 0.622794
Click to view 3D structure	5-hydroxytryptamine receptor 1A	P19327	Rattus norvegicus	Predicted (SEA)	Prediction Confidence Score 0.475 Applicability Domain 0.544 Statistical Significance 0.006 Supporting Reference Compounds 541 E-value 46.476
Click to view 3D structure	5-hydroxytryptamine receptor 5A	P47898	Humans	Predicted (SEA)	Prediction Confidence Score 0.447 Applicability Domain 0.544 Statistical Significance 0.001 Supporting Reference Compounds 225 E-value 8.01847
Click to view 3D structure	5-hydroxytryptamine receptor 7	P34969	Humans	Predicted (SEA)	Prediction Confidence Score 0.443 Applicability Domain 0.544 Statistical Significance 0.0067 Supporting Reference Compounds 565 E-value 52.159
Click to view 3D structure	5-hydroxytryptamine receptor 1B	P28564	Rattus norvegicus	Predicted (SEA)	Prediction Confidence Score 0.438 Applicability Domain 0.544 Statistical Significance 0.0017 Supporting Reference Compounds 154 E-value 13.0787
Click to view 3D structure	5-hydroxytryptamine receptor 2B	P41595	Humans	Predicted (SEA)	Prediction Confidence Score 0.407 Applicability Domain 0.473 Statistical Significance 0.0075 Supporting Reference Compounds 686 E-value 58.6983
Click to view 3D structure	5-hydroxytryptamine receptor 1F	P30939	Humans	Predicted (SEA)	Prediction Confidence Score 0.406 Applicability Domain 0.627 Statistical Significance 2.40e-04 Supporting Reference Compounds 45 E-value 1.86838
Click to view 3D structure	5-hydroxytryptamine receptor 6	P50406	Humans	Predicted (SEA)	Prediction Confidence Score 0.402 Applicability Domain 0.473 Statistical Significance 0.0085 Supporting Reference Compounds 536 E-value 66.5611
Click to view 3D structure	5-hydroxytryptamine receptor 2C	P08909	Rat	Predicted (SEA)	Prediction Confidence Score 0.4 Applicability Domain 0.544 Statistical Significance 0.0045 Supporting Reference Compounds 185 E-value 35.4214
Click to view 3D structure	D(2) dopamine receptor	P14416	Humans	Predicted (SEA)	Prediction Confidence Score 0.39 Applicability Domain 0.544 Statistical Significance 0.0236 Supporting Reference Compounds 1103 E-value 183.88
Click to view 3D structure	D(1A) dopamine receptor	P18901	Rattus norvegicus	Predicted (SEA)	Prediction Confidence Score 0.385 Applicability Domain 1.0 Statistical Significance 0.0063 Supporting Reference Compounds 206 E-value 49.4343
Click to view 3D structure	5-hydroxytryptamine receptor 7	P32305	Rattus norvegicus	Predicted (SEA)	Prediction Confidence Score 0.38 Applicability Domain 0.491 Statistical Significance 0.0053 Supporting Reference Compounds 115 E-value 41.4158
Click to view 3D structure	5-hydroxytryptamine receptor 1E	P28566	Humans	Predicted (SEA)	Prediction Confidence Score 0.373 Applicability Domain 0.544 Statistical Significance 0.0015 Supporting Reference Compounds 139 E-value 11.7552
Click to view 3D structure	Sodium-dependent serotonin transporter	P31645	Humans	Predicted (SEA)	Prediction Confidence Score 0.355 Applicability Domain 0.491 Statistical Significance 0.0192 Supporting Reference Compounds 593 E-value 149.315
Click to view 3D structure	5-hydroxytryptamine receptor 2B	P30994	Rattus norvegicus	Predicted (SEA)	Prediction Confidence Score 0.354 Applicability Domain 0.473 Statistical Significance 0.001 Supporting Reference Compounds 40 E-value 8.09632
Click to view 3D structure	5-hydroxytryptamine 1D receptor	Q8MI13	Bos taurus	Predicted (SEA)	Prediction Confidence Score 0.347 Applicability Domain 0.544 Statistical Significance 5.00e-05 Supporting Reference Compounds 5 E-value 0.389246
Click to view 3D structure	5-hydroxytryptamine receptor 3A	P46098	Humans	Predicted (SEA)	Prediction Confidence Score 0.34 Applicability Domain 0.544 Statistical Significance 0.0082 Supporting Reference Compounds 228 E-value 63.8364
Click to view 3D structure	5-hydroxytryptamine receptor 1D	Q60484	Cavia porcellus	Predicted (SEA)	Prediction Confidence Score 0.328 Applicability Domain 0.473 Statistical Significance 3.20e-04 Supporting Reference Compounds 10 E-value 2.49118
Click to view 3D structure	5-hydroxytryptamine receptor 1B	P28222	Humans	Known	Zolmitriptan binds with high affinity to human 5-HT_1B and 5-HT_1D receptors leading to cranial blood vessel constriction. Current theories proposed to explain the etiology of migraine headache suggest that symptoms are due to local cranial vasodilatation and/or to the release of sensory neuropeptides (vasoactive intestinal peptide, substance P and calcitonin gene-related peptide) through nerve endings in the trigeminal system. The therapeutic activity of zolmitriptan for the treatment of migraine headache can most likely be attributed to the agonist effects at the 5HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.
Click to view 3D structure	5-hydroxytryptamine receptor 1D	P28221	Humans	Known	Zolmitriptan binds with high affinity to human 5-HT_1B and 5-HT_1D receptors leading to cranial blood vessel constriction. Current theories proposed to explain the etiology of migraine headache suggest that symptoms are due to local cranial vasodilatation and/or to the release of sensory neuropeptides (vasoactive intestinal peptide, substance P and calcitonin gene-related peptide) through nerve endings in the trigeminal system. The therapeutic activity of zolmitriptan for the treatment of migraine headache can most likely be attributed to the agonist effects at the 5HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.
Click to view 3D structure	5-hydroxytryptamine receptor 1A	P08908	Humans	Known	Not Available
Click to view 3D structure	5-hydroxytryptamine receptor 1F	P30939	Humans	Known	Zolmitriptan binds with high affinity to human 5-HT_1B and 5-HT_1D receptors leading to cranial blood vessel constriction. Current theories proposed to explain the etiology of migraine headache suggest that symptoms are due to local cranial vasodilatation and/or to the release of sensory neuropeptides (vasoactive intestinal peptide, substance P and calcitonin gene-related peptide) through nerve endings in the trigeminal system. The therapeutic activity of zolmitriptan for the treatment of migraine headache can most likely be attributed to the agonist effects at the 5HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.
Click to view 3D structure	5-hydroxytryptamine receptor 4	Q13639	Humans	Known	Zolmitriptan binds with high affinity to human 5-HT_1B and 5-HT_1D receptors leading to cranial blood vessel constriction. Current theories proposed to explain the etiology of migraine headache suggest that symptoms are due to local cranial vasodilatation and/or to the release of sensory neuropeptides (vasoactive intestinal peptide, substance P and calcitonin gene-related peptide) through nerve endings in the trigeminal system. The therapeutic activity of zolmitriptan for the treatment of migraine headache can most likely be attributed to the agonist effects at the 5HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.

Concentrations

Not Available

External Links

DrugBank ID

DB00315

HMDB ID

HMDB0014460

FooDB ID

Not Available

Phenol Explorer ID

Not Available

KNApSAcK ID

Not Available

BiGG ID

Not Available

BioCyc ID

Not Available

METLIN ID

Not Available

PDB ID

Not Available

Wikipedia Link

Chemspider ID

ChEBI ID

PubChem Compound ID

Kegg Compound ID

YMDB ID

Not Available

ECMDB ID

Not Available

References

Synthesis Reference

Islam Aminul, Bhar Chandan, Katam Sahadev, “Process for preparing optically pure zolmitriptan.” U.S. Patent US20050245585, issued November 03, 2005.

MSDS

Not Available

General References

Pascual J: [Mechanism of action of zolmitriptan]. Neurologia. 1998 Oct;13 Suppl 2:9-15. [PubMed: 9859690]
Martin GR: Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine. Cephalalgia. 1997 Oct;17 Suppl 18:4-14. [PubMed: 9399012]
Drugs.com - http://www.drugs.com/cons/Zolmitriptan.html
RxList: The Internet Drug Index (2009). - http://www.rxlist.com/

Zolmitriptan (CED0006350)

Structure for CHEM002167: Zolmitriptan

Structure